Biotech & Life SciencesFood & AgricultureHealthcareData & AnalyticsFintechEnterprise SoftwareCybersecurity
Viking Global Investors employs a multi-faceted investment strategy, primarily focusing on long/short equity, long-only equity, and private equity across global markets. Their approach is rooted in deep, fundamental research to identify high-quality companies with strong growth potential, often maintaining a diversified portfolio with a preference for technology and healthcare sectors.
40% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Average disclosed round size is $126.0M (across 56 rounds with reported amounts).
Portfolio
57
Fund Size
$57B
Top Stage
Growth
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
57 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| WWomen's Health, Sports & Performance Institute | Unknown | $50M | Jan 2026 |
 Antheia | Series C | $56M | Jun 2025 |
 Triveni Bio Inc. | Series B | $115M | Oct 2024 |
 Magenta Medical | Growth | $105M | Jul 2024 |
| Antheia | Unknown | $17M | Jul 2024 |
 AlphaSense | Growth | $650M | Jun 2024 |
 Diagonal Therapeutics | Series A | $128M | Apr 2024 |
 Valsoft | Growth | $170M | Jan 2024 |
 Human Immunology Biosciences (HI-Bio) | Series B | $95M | Jan 2024 |
| Triveni Bio Inc. | Series A | $92M | Oct 2023 |
| AlphaSense | Series E | $150M | Sep 2023 |
 Solarea Bio | Series B | $15M | May 2023 |
| AlphaSense | Series D | $100M | Apr 2023 |
 Vector BioMed | Seed | — | Jan 2023 |
 Pearl Health | Series B | $75M | Jan 2023 |
 Mantra Bio | Series A | $9M | Jan 2023 |
| AlphaSense | Series D | $225M | Jun 2022 |
 Dock | Growth | $110M | May 2022 |
 Color | Series E | $100M | Nov 2021 |
 Cloudbeds | Series D | $150M | Nov 2021 |
| GGlobal Processing Services | Growth | $300M | Oct 2021 |
| AlphaSense | Series C | $180M | Sep 2021 |
 Apeel Sciences | Series E | $250M | Aug 2021 |
 Talkdesk | Series D | $230M | Aug 2021 |
 Genomatica | Series C | $118M | Jul 2021 |
Page 1 of 3
Top Co-Investors
Andreessen Horowitz7 shared
Goldman Sachs5 shared
SoftBank Vision Fund3 shared
Atlas Venture3 shared
OrbiMed3 shared
S2G Ventures3 shared
Franklin Templeton3 shared
Casdin Capital3 shared
Allen & Company3 shared
EDBI2 shared
Goldman Sachs Alternatives2 shared
Willoughby Capital2 shared
BoxGroup2 shared
Illumina Ventures2 shared
General Atlantic2 shared
Cormorant Asset Management2 shared
Invus2 shared
Riverwood Capital2 shared
BlackRock2 shared
Last updated: 12 April 2026